Tag Archives: Endpoints

Eureka Thera’s CAR-T treatment shrinks liver cancer in small study. What’s the big deal? Just ask Sloan-Kettering and Germany’s Boehringer.

      No Comments on Eureka Thera’s CAR-T treatment shrinks liver cancer in small study. What’s the big deal? Just ask Sloan-Kettering and Germany’s Boehringer.

The News: Eureka Therapeutics Inc., a closely held biotechnology company, said that liver cancer patients getting its CAR-T therapy responded to the treatment, one of the first times the immune-system… Read more »

Investors pour $76 million into B round for Cortexyme’s “new” approach to Alzheimer’s. No, it doesn’t target Amyloid beta (Aβ); it’s bacterial and getting support from Pfizer, Paul Allen.

      No Comments on Investors pour $76 million into B round for Cortexyme’s “new” approach to Alzheimer’s. No, it doesn’t target Amyloid beta (Aβ); it’s bacterial and getting support from Pfizer, Paul Allen.

The News: With the evidence increasingly weighing in against amyloid beta as the best solo target for Alzheimer’s, startup Cortexyme Inc. (South San Francisco) has identified a brand-new target and… Read more »

Biotech IPO rain dance continues and not just in the USA. My take on where to place your bets.

      No Comments on Biotech IPO rain dance continues and not just in the USA. My take on where to place your bets.

It’s been said that biotechs are among the riskiest of initial public offerings due to the dualistic nature of their meds: they either succeed or they flop. There’s usually no… Read more »

Innovent Biologics epitomizes how China, not Russia, quickly becoming real threat to US biotech supremacy.

      No Comments on Innovent Biologics epitomizes how China, not Russia, quickly becoming real threat to US biotech supremacy.

The News: China’s Innovent Biologics Inc. has raised $150 million in a Series E crossover round, with Capital Group Private Markets picking up $90 million of the mega-round, according to Endpoints. The… Read more »

Transpacific biotech Engine Biosciences raises $10 million in Southeast Asia’s largest life sciences seed round.

      No Comments on Transpacific biotech Engine Biosciences raises $10 million in Southeast Asia’s largest life sciences seed round.

The News: Life sciences startups in Asia just got another shot in the arm with the $10 million investment in Engine Biosciences Pte. Ltd.–a biotech company that’s applying machine learning to… Read more »

Ablynx soars 60% on Novo’s latest hostile bid; grab a piece of this Belgian biotech because the real action’s just starting.

      No Comments on Ablynx soars 60% on Novo’s latest hostile bid; grab a piece of this Belgian biotech because the real action’s just starting.

The News: Denmark’s Novo Nordisk A/S (Copenhagen), the world’s biggest insulin maker, went public Monday (January 8, 2018) with a €2.6-billion ($3.1 billion) bid for Belgian biotech group Ablynx NV… Read more »

Patients lose, lawyers win, as AbbVie does deal with Amgen to delay Humira biosim.

      No Comments on Patients lose, lawyers win, as AbbVie does deal with Amgen to delay Humira biosim.

The News: Amgen Inc. (Thousand Oaks CA) has agreed to delay the US launch of its FDA-approved biosimilar version of AbbVie Inc.’s (North Chicago) Humira (adalimumab) until 2023, under a… Read more »

Zai Lab’s U.S. IPO marks another white-hot Chinese offering that begs the question: why are these Asian offerings so special?

      No Comments on Zai Lab’s U.S. IPO marks another white-hot Chinese offering that begs the question: why are these Asian offerings so special?

The News: Shang­hai-based biotech Zai Lab Ltd. raised $150 mil­lion from its up­sized IPO last Wednes­day (September 20, 2017), sell­ing 8.3 mil­lion shares at $18 each. After trad­ing began, the… Read more »

Novartis CEO Jimenez is stepping down; does successor Narasimhan have the right stuff to take the reins in 2018?

      No Comments on Novartis CEO Jimenez is stepping down; does successor Narasimhan have the right stuff to take the reins in 2018?

The News: Swiss pharmaceuticals titan Novartis AG (Basel) will get a new chief executive in 2018–Dr. Vasant Narasimhan (pdf)–after Joseph Jimenez proclaimed his upcoming retirement effective in February. Jimenez has… Read more »

Merck’s Frazier leads the way quitting Trump business council after Charlottesville; J&J’s Gorsky’s bail way too late.

      No Comments on Merck’s Frazier leads the way quitting Trump business council after Charlottesville; J&J’s Gorsky’s bail way too late.

The News: One day after J&J chief exec Alex Gorsky pub­licly com­mit­ted to stay­ing on Pres­i­dent Don­ald Trump’s man­u­fac­tur­ing coun­cil, he abruptly re­versed course–just as the sud­den mass departure of ex­ec­u­tives forced… Read more »